NCHR and other non-profit organizations sent a letter urging increased FY 2025 appropriations for the Consumer Product Safety Commission. CPSC funding should not be subject to cuts or restrictions that would further undermine its ability to protect the public from hazardous consumer products.
Read More »On Health Policy
Testimony of Dr. Diana Zuckerman at the Tobacco Products Scientific Advisory Committee Meeting on General Snus
June 26, 2024: NCHR testified at the FDA Advisory Committee about the problems with safety data for General Snus smokeless tobacco and questioned whether they deserve to be labeled as safer than cigarettes.
Read More »NCHR Testimony at the FDA Listening Session on Advisory Committee Meetings
June 13, 2024: NCHR testified at the FDA listening session on Advisory Committee reform. We expressed concerns with the miscategorization of Consumer Representatives on AdComs and the ability of individuals with prior financial ties to industry to serve on these committees.
Read More »The Patient, Consumer, and Public Health Coalition Testified at an FDA Listening Session on Advisory Committees
June 13, 2024: The Patient, Consumer, and Public Health coalition testified at the FDA listening session on Advisory Committee reform. We expressed concerns with the miscategorization of Consumer Representatives on AdComs, the inherent conflicts of interests of committee members, and inadequate training provided to appointees.
Read More »NCHR’s Public Comment on Early Alzheimer’s Disease: Developing Drugs for Treatment; Draft Guidance for Industry
June 10, 2024: NCHR disagrees with assumptions made in FDA guidance aimed at developing drugs for treatment of early stages of Alzheimer’s dementia.
Read More »